20 https://www.biospace.com/articlesrss/ Thu, 04 Jan 2024 04:04:24 -0500 Thu, 04 Jan 2024 04:04:24 -0500 BioSpace Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND. https://www.biospace.com/article/releases/innate-pharma-announces-u-s-fda-lifts-partial-clinical-hold-on-lacutamab-clinical-program/ Thu, 04 Jan 2024 00:06:00 -0500 https://www.biospace.com/article/releases/innate-pharma-announces-u-s-fda-lifts-partial-clinical-hold-on-lacutamab-clinical-program/ Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members. https://www.biospace.com/article/releases/innate-pharma-strengthens-leadership-and-appoints-two-new-members-to-its-executive-board/ Thu, 04 Jan 2024 00:06:00 -0500 https://www.biospace.com/article/releases/innate-pharma-strengthens-leadership-and-appoints-two-new-members-to-its-executive-board/ Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450. https://www.biospace.com/article/releases/burning-rock-announces-receipt-of-notification-from-nasdaq-jan-04-2024/ Thu, 04 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/releases/burning-rock-announces-receipt-of-notification-from-nasdaq-jan-04-2024/ Laekna announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. https://www.biospace.com/article/releases/laekna-announces-poster-presentation-on-internally-discovered-antibody-for-nash-liver-fibrosis-at-nash-tag-2024/ Thu, 04 Jan 2024 00:46:00 -0500 https://www.biospace.com/article/releases/laekna-announces-poster-presentation-on-internally-discovered-antibody-for-nash-liver-fibrosis-at-nash-tag-2024/ Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share. https://www.biospace.com/article/releases/longboard-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock/ Thu, 04 Jan 2024 00:46:00 -0500 https://www.biospace.com/article/releases/longboard-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock/ Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share. https://www.biospace.com/article/releases/keros-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock/ Thu, 04 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/releases/keros-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock/ SELLAS Life Sciences Group, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering. https://www.biospace.com/article/releases/sellas-life-sciences-announces-proposed-public-offering-jan-04-2024/ Thu, 04 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/releases/sellas-life-sciences-announces-proposed-public-offering-jan-04-2024/ Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family of products. https://www.biospace.com/article/releases/kuros-biosciences-announces-three-advancements-related-to-its-magnetostm-portfolio-including-impressive-fusion-data-from-maxa-prospective-randomized-clinical-trial-and-two-510-k-clearances-from-fda/ Thu, 04 Jan 2024 00:20:00 -0500 https://www.biospace.com/article/releases/kuros-biosciences-announces-three-advancements-related-to-its-magnetostm-portfolio-including-impressive-fusion-data-from-maxa-prospective-randomized-clinical-trial-and-two-510-k-clearances-from-fda/ ANGLE plc is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient's cancer and how this may be treated. https://www.biospace.com/article/releases/angle-plc-announces-breakthrough-clinical-results/ Thu, 04 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/releases/angle-plc-announces-breakthrough-clinical-results/ Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases. https://www.biospace.com/article/releases/sitryx-announces-collaboration-partner-lilly-has-commenced-a-phase-1-study-of-sit-011-for-chronic-autoimmune-and-inflammatory-diseases/ Thu, 04 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/releases/sitryx-announces-collaboration-partner-lilly-has-commenced-a-phase-1-study-of-sit-011-for-chronic-autoimmune-and-inflammatory-diseases/ ]]>In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis. https://www.biospace.com/article/boehringer-inks-potential-2b-deal-with-ribo-targets-nash-with-sirna-therapies-/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/boehringer-inks-potential-2b-deal-with-ribo-targets-nash-with-sirna-therapies-/ ]]>Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months. https://www.biospace.com/article/nextgen-class-of-2024-top-life-sciences-startups-to-watch-this-year/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/nextgen-class-of-2024-top-life-sciences-startups-to-watch-this-year/ ]]>The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools. https://www.biospace.com/article/goldman-sachs-closes-first-life-sciences-vc-fund-with-650m-in-equity-/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/goldman-sachs-closes-first-life-sciences-vc-fund-with-650m-in-equity-/ ]]>Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace. https://www.biospace.com/article/2024-predictions-for-biotech-m-and-as-/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/2024-predictions-for-biotech-m-and-as-/ ]]>Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace's tenth annual NextGen list of the hottest new life sciences companies. https://www.biospace.com/article/the-top-life-sciences-startups-to-watch-this-year/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/the-top-life-sciences-startups-to-watch-this-year/ ]]>The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys. https://www.biospace.com/article/fda-approvals-jumped-50-percent-in-2023-dominated-by-novel-drug-nods-for-pfizer/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/fda-approvals-jumped-50-percent-in-2023-dominated-by-novel-drug-nods-for-pfizer/ ]]>Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news. https://www.biospace.com/article/longboard-stock-skyrockets-on-promising-epilepsy-data-launches-150m-public-offering/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/longboard-stock-skyrockets-on-promising-epilepsy-data-launches-150m-public-offering/ ]]>It wasn't a merry end to 2023 for Amgen or Zealand Pharma, which received Complete Response Letters for Lumakras and for dasiglucagon in congenital hyperinsulinism. https://www.biospace.com/article/biospace-fda-decision-tracker-2023-biomarin-celltrans-pfizer-and-opko-health/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/biospace-fda-decision-tracker-2023-biomarin-celltrans-pfizer-and-opko-health/ ]]>Agios Pharmaceuticals met the primary endpoint in a late-stage trial investigating its drug mitapivat in treating adults with non-transfusion-dependent alpha- or beta-thalassemia. https://www.biospace.com/article/agios-aces-phase-iii-study-of-mitapivat-in-treating-adults-with-alpha-or-beta-thalassemia/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/agios-aces-phase-iii-study-of-mitapivat-in-treating-adults-with-alpha-or-beta-thalassemia/ ]]>Anavex Life Sciences' stock dropped by more than a third in value on Tuesday after results for a Phase II/III Rett syndrome study failed to impress investors. https://www.biospace.com/article/anavex-s-stock-nosedives-after-posting-trial-results-for-rett-syndrome/ Wed, 03 Jan 2024 00:00:00 -0500 https://www.biospace.com/article/anavex-s-stock-nosedives-after-posting-trial-results-for-rett-syndrome/